View of PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials

Return to Article Details PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials Download Download PDF